FY2025 results mark the conclusion of Vision 2025 with highest sales and net profit in company’s history
Q1/2026: +2.3% sales growth in constant currency despite extreme weather conditions
Dr. Howard Purcell, President and CEO of the New England College of Optometry (NECO), named Chairman of the Advisory Board
Six renowned Optometric Doctors (ODs) join as members
Panel will advise Fielmann Group and Fielmann USA Top Management on strategic development of business in US vision care, providing deep expertise, especially in medical eyecare
Customer-centric philosophy delivers consistently high customer satisfaction of around 90%
Vision 2025 concluded with +€1bn global sales and nearly +€200m Adj. EBITDA compared to 2018
Focus on efficiency drives results: Adj. EBITDA margin reaches 25% in Europe and 24% at Group level in FY2025
US platform profitability jumps to 16.2% Adj. EBITDA margin in FY2025 (2024: 9.9%)
Management confirms FY2025 guidance, expects outperformance of Vision 2025 goals
Focus on profitability pays off: 9M/2025 Adj. EBITDA increases by +1.7%pts. vs. 9M/2024
US integration concluded, business model transformation ongoing, profitability developing favorably
Scientific evaluation of Fielmann’s Eye Health Checkup in Germany
Fielmann customers in Hamburg can now opt for an ophthalmologist exam as part of the scientific study
ZEISS Vision Care announced today that it has entered into a definitive agreement to acquire a 10% stake in Ocumeda at a total company valuation of €100m from Fielmann Group
Ocumeda is one of the leading tele-ophthalmology platforms in Europe connecting about 300,000 active patients and 700 optical retail stores with ophthalmologists and the medical community
